Insight

Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer

Paolo Ciracì/LinkedIn

Nov 20, 2024, 19:12

Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer

A recent paper by Paolo Ciracì, Medical Oncology Resident at the University Hospital of Pisa, was mentioned by Nieves Martinez Lago, Medical Oncologist at the University Hospital Complex of Ferrol, on X:

“Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

FTD/TPI+BEV, REG and FRU for unselected patients.
Targeted Therapies for patients With Oncogenic Driver Molecular Alterations.
Rechallenge antiEGFR in patients ctDNA RAS/BRAF wild-type.”

“Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm”

Authors: Paolo Ciracì, Vittorio Studiale, Ada Taravella, Carlotta Antoniotti, Chiara Cremolini.

For more posts like this, visit oncodaily.com.

Ada Taravella cancer Carlotta Antoniotti Chiara Cremolini clinical trials Metastatic colorectal cancer Nieves Martinez Lago OncoDaily Oncology Paolo Ciracì Vittorio Studiale

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Special Coverage